D
David L. Nelson
Researcher at Eli Lilly and Company
Publications - 60
Citations - 4678
David L. Nelson is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Agonist & Receptor. The author has an hindex of 26, co-authored 59 publications receiving 4422 citations.
Papers
More filters
Journal ArticleDOI
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.
Frank P. Bymaster,Jason Katner,David L. Nelson,Susan K. Hemrick-Luecke,Penny G. Threlkeld,John H. Heiligenstein,S Michelle Morin,Donald R. Gehlert,Kenneth W. Perry +8 more
TL;DR: It is hypothesized that the atomoxetine-induced increase of catecholamines in PFC, a region involved in attention and memory, mediates the therapeutic effects of atomxetine in ADHD.
Journal ArticleDOI
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.
Yansheng Du,Zhizhong Ma,Suizhen Lin,Richard Dodel,Feng Gao,Kelly R. Bales,Lazarose C. Triarhou,Eyassu Chernet,K.W. Perry,David L. Nelson,Susan H. Luecke,Lee A. Phebus,Frank P. Bymaster,Steven M. Paul,Steven M. Paul +14 more
TL;DR: The results suggest that minocycline blocks MPTP neurotoxicity in vivo by indirectly inhibiting MPTP/MPP+-induced glial iNOS expression and/or directly inhibiting NO-induced neurotoxicity, most likely by inhibiting the phosphorylation of p38 MAPK.
Journal ArticleDOI
Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors
Frank P. Bymaster,Laura J. Dreshfield-Ahmad,Penny G. Threlkeld,Janice L Shaw,Linda K. Thompson,David L. Nelson,Susan K. Hemrick-Luecke,David T.W. Wong +7 more
TL;DR: Duloxetine more potently blocks 5-HT and NE transporters in vitro and in vivo than venlafaxine.
Journal ArticleDOI
Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro
Frank P. Bymaster,David L. Nelson,Neil W. DeLapp,Julie F. Falcone,Kris Eckols,Lewis L. Truex,Foreman Mark Mortensen,Virginia L. Lucaites,David O. Calligaro +8 more
TL;DR: Olanzapine was an antagonist at all receptors investigated and was a particularly potent antagonist at 5-HT2A, 5- HT2B, 5,HT2C, alpha 1-adrenergic and histamine H1 receptors.
Journal ArticleDOI
Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan:
David L. Nelson,Lee A. Phebus,Kirk W. Johnson,David B. Wainscott,Marlene L. Cohen,David O. Calligaro,Yao-Chang Xu +6 more
TL;DR: Lasmiditan presents a unique pyridinoyl-piperidine scaffold not found in any other antimigraine class, whose chemical structure and pharmacological profile clearly distinguish it from the triptans.